Originally published Sept. 2.

NEW YORK (GenomeWeb) – OncoMed Pharmaceuticals announced this week that the US Food and Drug Administration has lifted its partial clinical hold that was keeping the firm from enrolling patients in Phase I studies of the WNT pathway inhibitor vantictumab.

The FDA lifted the hold after reviewing OncoMed's plans to manage bone-related adverse events observed in these early stage studies. The company told PGx Reporter that it is currently not providing details of its altered clinical trial plan.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.